- Study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population.
- There were no new safety signals identified and the safety profile was comparable between treatment arms.
PR Newswire
INDIANAPOLIS, Jan. 18, 2019